A second attempt by Nabriva Therapeutics plc to win U.S. approval for the antibiotic Contepo (fosfomycin) has been undone by COVID-19. Manufacturing issues stymied the original NDA. This time, restrictions of FDA staff travel to Europe sunk the venture, leading to a new complete response letter (CRL) for the candidate as a potential treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis.
PARIS – Stilla Technologies SAS, of Villejuif, France, is supplying a new, cost-effective approach for COVID-19 testing by combining its digital polymerase chain reaction (PCR) technology with the group testing method. “This approach greatly increases testing capacity and meets the highest quality standards,” Rémi Dangla, co-founder and CEO of Stilla Technologies, told BioWorld.
COLOMBIA – The COVID-19 pandemic has put Latin America’s biotech sector under extreme pressure and highlighted flaws in the ecosystem throughout the region, not the least of which is a lack of viable networks to facilitate cooperation.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Anpac Bio, Beijing Yuan Jian Health Management, Koru Medical Systems, Masimo, Pixium, Seizure Tracker, Tuberous Sclerosis Alliance.
PERTH, Australia – Australia’s largest life science investment fund is pressing the government for an urgent COVID-19 response package to support the country’s AU$170 billion (US$117 billion) life sciences sector that is struggling to survive in a post-COVID-19 ecosystem.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acasti, Ampio, Ascentage, Beigene, Innovent, Nymox, Ovid, Plakous, Redhill, Regeneron, Sanofi.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Acerus, Achilles Vaccines, Adamis, Assembly, Hemostemix, Immuron, Kane Biotech, Merck, Oncolys, Oryzon, Themis, Tiziana.
RSS
